BioCentury | Apr 4, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: March 2018

New Therapeutic Targets and Biomarkers: March 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during March 2018. Therapeutic targets are defined as any protein, gene or other...
BioCentury | Apr 3, 2018
Translation in Brief

Strong-arming drug delivery

In a Nature Communications study, a Harvard team developed extracellular vesicles that can deliver a variety of macromolecular cargo inside target cells or tissues, paving the way for therapeutics against traditionally intractable intracellular targets. Previously,...
BioCentury | Mar 28, 2018
Distillery Techniques

Drug delivery

TECHNOLOGY: Nanoparticles ARRDC1-containing microvesicles could be used to deliver therapeutic macromolecules. The method involves engineering HEK cells to express ARRDC1 for enhanced formation of extracellular microvesicles that incorporate three types of cargo co-expressed in the...
BioCentury | Sep 15, 2016
Distillery Therapeutics

Therapeutics: MLX interacting protein (MLXIP); thioredoxin interacting protein (TXNIP); arrestin domain containing 4 (ARRDC4)

...disease INDICATION: Obesity Cell culture and mouse studies suggest inhibiting the MLXIP / TXNIP / ARRDC4...
...a MLXIP inhibitor tool compound increased insulin-stimulated glucose uptake and decreased expression of TXNIP and ARRDC4...
...mice fed a high-fat diet, another MLXIP inhibitor tool compound decreased expression of TXNIP and ARRDC4...
BioCentury | Oct 27, 2011
Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Obesity Arrestin domain containing 3 (ARRDC3) Mouse and human sample studies suggest decreasing levels of ARRDC3 could help treat male obesity. In human adipose...
Items per page:
1 - 5 of 5